- Novo Nordisk plans to cut 9,000 jobs globally, including 5,000 in Denmark.
- The restructuring aims to save DKK 8bn annually by the end of 2026.
- One-off restructuring costs are expected to be DKK 8bn.
- 2025 operating profit growth outlook is adjusted to 4-10% at CER.
Transformation Plan
Novo Nordisk is undergoing a company-wide transformation to streamline operations and enhance decision-making speed. The initiative aims to reallocate resources towards growth opportunities in diabetes and obesity, addressing the rising global demand and increased market competition.
Workforce Reduction
The company plans to reduce its global workforce by approximately 9,000 positions out of 78,400, with around 5,000 job cuts expected in Denmark. This move is part of a strategy to simplify the organization and reduce costs.
Financial Impact
The restructuring is expected to deliver annualized savings of DKK 8 billion by the end of 2026. However, it will incur one-off restructuring costs of DKK 8 billion, impacting the 2025 operating profit growth outlook, which is now adjusted to 4-10% at constant exchange rates (CER).
Investment Focus
Savings from the restructuring will be redirected to growth opportunities in diabetes and obesity, including commercial execution initiatives and R&D programs. The company aims to enhance organizational focus, performance culture, and cost efficiencies.
